Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPI with Camrelizumab or Apatinib in High-grade Osteosarcoma
NCT04351308Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- May 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab and Rivoceranib in osteosarcoma (OS) (3 arms), sponsored by Peking University People's Hospital. Primary endpoint: Event-Free Survival Rate at 2 years. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT04351308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04351308.